Supplementary Table 7. Clinical profiles of subgroups by pre-stroke statin use

Variables	Pre-stroke statin use: yes			Pre-stroke statin use: no		
	No statins (n=51)	Early statins (n=149)	P	No statins (n=232)	Early statins (n=425)	P
Demographic information						
Age	73.1±9.3	70.9±10.4	0.15	69.9±13.5	67.0±12.9	0.01
Male sex	25 (49.0)	86 (57.7)	0.28	119 (51.3)	264 (62.1)	0.01
Premorbid mRS score=0	41 (80.4)	122 (81.9)	0.81	185 (79.7)	387 (91.1)	<0.01
Admission year, 2011–2015	32 (62.7)	117 (78.5)	0.03	126 (54.3)	317 (74.6)	<0.01
Stroke information						
NIHSS score at arrival	15 (8–19)	12 (6–18)	0.21	15 (9–20)	11 (6–17)	<0.01
Onset to treatment delay (hour)	3.2 (1.8–6.4)	2.8 (1.6–7.9)	0.92	2.7 (1.7–5.8)	2.9 (1.7–8.8)	0.06
Recanalization treatment			0.43			<0.01
Intravenous thrombolysis alone	14 (27.5)	54 (36.2)		57 (24.6)	155 (36.5)	
Endovascular therapy alone	15 (29.4)	44 (29.5)		73 (31.5)	150 (35.3)	
Combined	22 (43.1)	51 (34.2)		102 (44.0)	120 (28.2)	
NIHSS score after treatment	15 (6.5–18.5)	9 (4–16)	0.01	14 (5.75–20)	8 (4–14)	<0.01
Stroke mechanism			0.45			<0.01
Large artery atherosclerosis	10 (19.6)	40 (26.8)		34 (14.7)	143 (33.6)	
Small vessel occlusion	0 (0)	6 (4.0)		1 (0.4)	26 (6.1)	
Cardioembolism	31 (60.8)	76 (51.0)		141 (60.8)	165 (38.8)	
Other determined cause	2 (3.9)	4 (2.7)		17 (7.3)	18 (4.2)	
Undetermined cause	8 (15.7)	23 (15.4)		39 (16.8)	73 (17.2)	
Vascular risk factors						
Hypertension	43 (84.3)	125 (83.9)	0.94	131 (56.5)	280 (65.9)	0.02
Diabetes	15 (29.4)	66 (44.3)	0.06	55 (23.7)	96 (22.6)	0.75
Hyperlipidemia	34 (66.7)	131 (87.9)	<0.01	11 (4.7)	50 (11.8)	<0.01
Atrial fibrillation	25 (49.0)	66 (44.3)	0.56	133 (57.3)	139 (32.7)	<0.01
Regular smoking	12 (23.5)	56 (37.6)	0.07	70 (30.2)	189 (44.5)	<0.01
Pre-stroke antithrombotics	40 (78.4)	108 (72.5)	0.40	113 (48.7)	117 (27.5)	<0.01
Pre-stroke statins	51 (100)	149 (100)	–	0 (0)	0 (0)	–
Laboratory information						
White cell count (μL)	8,038±2,564	8,004±2,940	0.94	8,328±3,646	8,570±3,107	0.39
Hemoglobin (g/dL)	13.3±2.1	13.4±1.8	0.83	13.4±2.0	13.8±2.1	0.01
Initial glucose (mg/dL)	141±55	141±51	0.96	136±48	135±52	0.89
HbA1c (%)	6.2±1.3	6.5±1.2	0.28	6.0±0.8	6.1±1.1	0.03
Total cholesterol (mg/dL)	157±32	152±41	0.40	161±35	179±43	<0.01
HDL cholesterol (mg/dL)	46±12	44±10	0.26	45±13	44±11	0.28
Triglycerides (mg/dL)	101±54	104±53	0.71	99±57	115±70	<0.01
LDL cholesterol (mg/dL)	90±29	87±37	0.51	96±28	111±37	<0.01
Systolic blood pressure (mmHg)	157±24	152±27	0.22	148±28	153±28	0.02
Diastolic blood pressure (mmHg)	81±14	80±16	0.94	81±17	83±19	0.11
Outcome information						
mRS score at 3 months			<0.01			<0.01
0	6 (11.8)	45 (30.2)		39 (16.8)	87 (20.5)	
1	3 (5.9)	23 (15.4)		22 (9.5)	89 (20.9)	
2	7 (13.7)	19 (12.8)		29 (12.5)	65 (15.3)	
3	5 (9.8)	17 (11.4)		27 (11.6)	67 (15.8)	
4	13 (25.5)	12 (8.1)		26 (11.2)	40 (9.4)	
5	9 (17.6)	19 (12.8)		44 (19.0)	50 (11.8)	
6	8 (15.7)	14 (9.4)		45 (19.4)	27 (6.4)	
Symptomatic HT	9 (17.6)	4 (2.7)	<0.01	21 (9.1)	18 (4.2)	0.01

Values are presented as mean±standard deviation, median (interquartile range), or number (%).
mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HT, hemorrhage transformation.